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Extranodal lymphomas (ENLs) comprise about a third of all non-Hodgkin lymphomas (NHL). Radiation therapy (RT) is
frequently used as either primary therapy (particularly for indolent ENL), consolidation after systemic therapy, salvage
treatment, or palliation. The wide range of presentations of ENL, involving any organ in the body and the spectrum of
histological sub-types, poses a challenge both for routine clinical care and for the conduct of prospective and retrospec-
tive studies. This has led to uncertainty and lack of consistency in RT approaches between centers and clinicians. Thus
far there is a lack of guidelines for the use of RT in the management of ENL. This report presents an effort by the In-
ternational Lymphoma Radiation Oncology Group (ILROG) to harmonize and standardize the principles of treatment of
ENL, and to address the technical challenges of simulation, volume definition and treatment planning for the most
frequently involved organs. Specifically, detailed recommendations for RT volumes are provided. We have applied
the same modern principles of involved site radiation therapy as previously developed and published as guidelines
for Hodgkin lymphoma and nodal NHL. We have adopted RT volume definitions based on the International Commission
on Radiation Units and Measurements (ICRU), as has been widely adopted by the field of radiation oncology for solid
tumors. Organ-specific recommendations take into account histological subtype, anatomy, the treatment intent, and other
treatment modalities that may be have been used before RT.  2015 The Authors. Published by Elsevier Inc. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Reprint requests to: Dr Joachim Yahalom, MD, Memorial Sloan-
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The heterogeneity of extranodal lymphomas (ENLs), and
the absence of prospective trial data or generally accepted
management guidelines, have led to a variety of volume
definitions, doses, and planning practices being imple-
mented at different centers for the radiation treatment of
ENLs. The lack of accepted standards has led to uncertainty
among both trainees and expert clinicians, and it affects the
reporting and analysis of treatment outcomes and patterns
of failure. To address this situation, an expert panel of
members of the International Lymphoma Radiation
Oncology Group (ILROG) steering committee was assem-
bled to review the available literature and to generate
appropriate consensus guidelines with a range of acceptable
options.
Definition
The ENLs are defined as lymphomas arising in an extra-
nodal organ or tissue. Overall, approximately one third of
non-Hodgkin lymphomas (NHL) present in an extranodal
site (1). In clinical practice, such lymphomas present pri-
marily with lesions wholly or predominantly confined to an
extranodal organ, with or without the involvement of
adjacent or draining lymph nodes. In some cases, extensive
involvement of adjacent lymph nodes or other tissues may
make the distinction between a primary ENL and a nodal
lymphoma challenging. Patients with disseminated lym-
phoma (Ann Arbor stage IIIE and IV disease) often have
extranodal spread, and these are not considered primary
ENL.
Evaluation
Adequate tissue sampling and careful histologic review is
critical. This may include, for example, targeting a biopsy
using endoscopic ultrasound in gastric lymphoma, or
positron emission tomography (PET) to identify areas
suggestive of potential transformation in indolent lym-
phomas. Thorough systemic staging will generally include
blood work to assess relevant organ function, computed
tomographic (CT) scans, fluorodeoxyglucose PET scans,
and bone marrow biopsy. Optimal locoregional assessment
may require ear, nose, and throat (ENT) examination,
endoscopic gastroduodenoscopy (EGD), or magnetic reso-
nance imaging (MRI). When preradiation therapy (RT)
chemotherapy is planned, baseline imaging is optimally
obtained with the patient in treatment position.
Principles of management
Although the specific RT issues and challenges for each
organ presentation will be addressed in detail, some broad
management principles apply. As is the case for nodallymphomas, key aspects of the management of indolent
versus aggressive ENL differ in relation to RT intent,
timing, field definition, and dose (2).
Indolent ENLdpredominantly marginal zone lym-
phoma (MZL) and follicular lymphoma (FL)doften pre-
sents with localized/organ-confined disease, and RT is
generally the primary curative modality (3). High local
control rates can be achieved with relatively modest
radiation doses, and local control often translates to cure
(4, 5). The role of surgery is largely limited to obtaining
diagnostic material. Although indolent ENL is highly
responsive to systemic therapy, the curative potential of
standard-dose systemic therapy has not been demonstrated
(6). Thus, in contrast to aggressive ENL, RT is usually used
as a single modality, and where systemic therapy has been
given, it generally does not have an impact on the RT
volume definition. Tumor multifocality within an organ and
limitations in imaging sensitivity often mandate irradiation
of a whole organ. RT may also be used as adjuvant therapy
with curative potential after prior surgery or chemotherapy
to treat potential microscopic residual disease, or as salvage
therapy for localized recurrences after surgery or chemo-
therapy. RT is also highly effective for patients with stage
IIIE/IV disease in whom palliation can be achieved with
very low radiation doses (5).
For aggressive localized ENL, systemic therapy is the
primary treatment modality unless patients are unfit for, or
refuse, such therapy. As is the case with nodal aggressive
NHL, RT is often used to consolidate the results of systemic
therapy, and it reduces the risk of local failure, potentially
translating into an improvement in progression-free and
overall survival. Decision making regarding the use of
adjuvant RT requires consideration of initial tumor bulk,
the response to systemic therapy, the likely morbidity of
RT, and the potential for salvage therapy. In contrast to
indolent ENL, radiation volumes may sometimes be limited
to part of an organ after an excellent response to systemic
therapy, inasmuch as systemic therapy may be assumed to
control adjacent sites of occult tumor infiltration. Patients
with an inadequate response to systemic therapy, or with
localized relapse, may benefit from salvage RT. This may
be given in conjunction with aggressive salvage chemo-
therapy (such as autologous stem cell transplantation) or,
where this is not feasible, as sole therapy. RT coverage will
often be more generous in a relapse setting. RT may pro-
vide effective palliation where potentially curative options
have been exhausted or are inappropriate.Radiation therapy dose
Indolent lymphomas
FL, MZL, and small lymphocytic lymphomas are highly
radioresponsive. RT is often used as the primary treatment
alone, and the dose range is normally between 20 and
30 Gy (4). The lower end of this dose range is particularly
relevant in radiosensitive organs such as the eye. Similar
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transformation to higher-grade disease is not present. For
symptom control, 4 Gy provides effective palliation for
most patients (5).
Aggressive lymphomas
For diffuse large B-cell lymphoma (DLBCL) and periph-
eral T-cell lymphoma (PTCL) involving extranodal sites, 30
to 36 Gy is an appropriate dose after a complete response
(CR) to first-line chemotherapy. A dose of 30 to 36 Gy is
also appropriate for patients who have had a CR to salvage
chemotherapy for relapsed or refractory disease (4). Pa-
tients with gross residual disease benefit from a higher dose
(40-45 Gy) (7). For patients unsuitable for aggressive
salvage chemotherapy, or who have residual, relapsed, or
progressive disease after such therapy, a dose of 45 to
55 Gy may be required to provide acceptable rates of local
disease control. Lower doses may be suitable when the
intent of treatment is symptom control only (8).
These recommended doses are considered suitable for
most patients with ENL and should be applied where no
specific dose is mentioned in the relevant section of the
text. A few specific entities, such as primary central ner-
vous system (CNS) lymphoma (PCNSL), natural killer
(NK)/T cell lymphoma of the head and neck, and cutaneous
lymphomas may require a different approach to RT dosing,
and this will be discussed in detail in the relevant sections.Radiation therapy fields
The standard definitions of extended field RT (EFRT),
involved field RT (IFRT), and the more recent involved
nodal RT (INRT) were taken from HL and nodal NHL and
do not fully address the planning requirements of ENL. In
developing the present ENL RT guidelines, ILROG has
applied the new concept of involved site RT (ISRT), as
recently published for HL and for nodal NHL (2, 9). The
ISRT paradigm limits the volume of RT either to the entire
involved organ or, in certain situations, to the involved
lesion only, depending on the organ involved, the type of
lymphoma, and the use of other treatment modalities.
The ISRT guidelines follow the field design principles
and volume definitions defined by the International Com-
mission on Radiation Units and Measurements (ICRU). The
ILROG recommendations are based on the ICRU Report 83
definitions of gross tumor volume (GTV), clinical target
volume (CTV), internal target volume (ITV), and planning
target volume (PTV) (10). Thus, for the first time, RT
volume definitions and treatment plan development for
patients with ENL follow principles similar to those used
for solid tumor volumes. Using ICRU definitions is
particularly helpful when 3-dimensional (3D) conformal
RT, intensity modulated RT (IMRT), imaged guided RT,
deep inspiration breath hold (DIBH), and other new plan-
ning and RT delivery tools are used. The ENL guidelines
have been detailed to address many common clinicalscenarios. They provide general principles for RT of ENL,
but importantly they require the clinician to adapt the field,
the dose, and the technique to the individual clinical setting.
Volume definitions
Gross tumor volume
TheGTV represents the part of an organ/structure involved by
lymphoma on clinical or radiologic assessment. If RT is the
sole therapy, theGTVequates to the tumor evident at diagnosis
(or after a biopsy). If RT follows a course of chemotherapy (or
surgery), one may define (1) a prechemotherapy (or surgery)
GTV, which represents the part of an organ/structure involved
on clinical or radiologic assessment before therapy; and (2) a
posttherapy GTV, which represents the residual macroscopic
abnormality after treatment.
Clinical target volume
The CTV encompasses macroscopic disease evident at the
time of simulation, and potential sites of microscopic dis-
ease. Microscopic disease may exist within the pre-
chemotherapy/surgery GTV, and this volume should be
transferred to the CT simulation study, preferably using
fusion of the available imaging (PET, CT, MRI, or a
combination of these). In many organs (such as stomach,
salivary glands, thyroid gland, and the CNS), lymphoma is
multifocal, and thus the organ is often treated in its entirety,
even if it initially appeared to be partially involved. When
adjacent tissue/structures have been involved, some or all of
the invaded structure/organ may be included in the CTV.
Uninvolved lymph nodes are not routinely included in the
CTV. However, first echelon nodes of uncertain status close
to the primary organ may be included, and if part of a nodal
group/chain is included in the CTV as part of the volume
delineation, it may be prudent to encompass that part of the
chain adequately. Exceptions from this paradigm are dis-
cussed when specific organs are reviewed.
In outlining the CTV the following points should be
considered:
 Quality and accuracy of imaging
 Concerns regarding changes in volume since imaging
 Patterns of the disease spread
 Likelihood of subclinical involvement
 Adjacent organ constraints
Internal target volume
The ITV is defined by the ICRU as the CTV plus a margin,
taking into account uncertainties in size, shape, and posi-
tion of the CTV within the patient. Some ENL organs may
move during respiration, may change their volume or shape
easily, or may make these changes and move as well.
Stomach and lung lesions are most often affected, and
either 4-dimensional (4D) CT or fluoroscopy should be
used to determine the ITV. In sites that are unlikely to
change shape or position during or between treatments,
outlining the ITV is not required.
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The PTV is an expansion of the CTV (or ITV, when relevant)
that accounts for setup uncertainties in patient positioning
and beam alignment during planning and through treatment
sessions. The CTV to PTV margin depends on immobili-
zation device, body site, and patient compliance. The typical
distance from CTV to PTV is usually 0.5 to 1 cm.
ENL-specific Guidelines by Organ
The following guidelines are presented for each organ in
which ENLs may occur.
Primary CNS Lymphoma
Most patients with PCNSL have DLBCL. RT is primarily
used as consolidative therapy after high-dose methotrex-
atedbased chemotherapy (11). Historically, doses of
around 45 Gy have been shown to decrease the risk of
progression or relapse after chemotherapy but at the cost of
significant neurotoxicity, particularly in patients older than
60 years (12). This has led to the more selective use of
lower RT doses in the range of 30 to 36 Gy, which appear to
be effective and less toxic. Ferreri et al (13) have not found
a benefit for increasing the dose beyond 36 Gy, and the role
of additional boost remains uncertain in the era of effective
chemotherapy. Recently, Memorial Sloan-Kettering Cancer
Center has reported long-term follow-up of a prospective
combined modality program using WBRT of 23.4 Gy after
a stringently defined chemotherapy-induced CR (Fig. 1).
This program was highly effective (14), and no significant
RT-related toxicity was detected even in elderly patients
(15, 16). Higher doses are required when RT is used as a
single modality therapy, either in patients who cannot
receive chemotherapy or as salvage treatment after
chemotherapy failure. Doses of 36 Gy have been shown to
be beneficial in a salvage setting, but the optimal dose and
the role of boost doses remain uncertain (17, 18). There is a
suggestion that lower dose per fraction (1.5 Gy) may also
reduce toxicity risk (18).
Generally, PCNSL is a multifocal process, with intra-
cranial involvement that is evident even far from radio-
logically detected sites (19). Thus, whole brain treatment is
the standard, with partial brain boost not shown to be
valuable (20). A retrospective study from Japan showed
that margins smaller than 4 cm around the lesion(s) were
associated with a higher failure rate and decreased survival
(21). Thus, adding a “lesion boost” field in a consolidation
setting is not recommended in most circumstances. The
value of a boost or partial brain RT in the refractory or
salvage setting has not been tested, but data from patho-
logic studies in patients who have experienced relapse
question its rationale (19). Cerebrospinal fluid involvement
should be treated with systemic/intrathecal chemotherapy,
and it is not standard of care to irradiate the whole spinal
axis.Because the optic nerve and the retina are considered
part of the CNS, PCNSL whole brain field design always
includes the posterior part of the orbits even if there is no
evidence of ocular disease. Because the eyes are occa-
sionally an isolated site of relapse and future ocular fields
may have to be added later, it is recommended to set the
isocenter of the WBRT field anteriorly for a potential future
isocentric match.
Slit-lamp examination of the eyes by an ophthalmologist
should be performed before field determination because it
will affect the anterior border of the field. If the eyes are
involved before chemotherapy is given, the WBRT should be
extended to include the entire globe to a dose of 30 to 36 Gy.
Recommendations for planning and treatment follow.
Preplanning studies
 Prechemotherapy and postchemotherapy MRI.
 Eye examination with slit lamp (before and after
chemotherapy if initial involvement).Field
 CTV: Whole brain including 1 or 2 upper cervical
vertebrae and the posterior aspect of the eyes. The iso-
center is set anteriorly and bisects the bony canthi (to
reduce divergence in possible future match to ocular
field). Alternatively, the anterior border of the PTV is set
with the isocenter 5 mm behind the lens (Fig. 1).
 If the eyes were originally involved, both eyes should be
included in their entirety in the WBRT field.
 The role of tumor site boost is uncertain and is not rec-
ommended by most experts.Dose
 Consolidation dose after MRI CR to chemotherapy:
24 Gy.
 WBRT after incomplete response to chemotherapy or
salvage: 36 Gy to 45 Gy (1.5 to 1.8 Gy/fraction).
 WBRT as primary treatment for noncandidates for
chemotherapy: 40 to 50 Gy (1.5 to 1.8 Gy/fraction).
 For palliation: WBRT dose is 30 to 36 Gy in 10 or 15
fractions.
Primary Intraocular Lymphoma
The diagnosis of primary intraocular lymphoma (PIOL) is
usually made by vitrectomy, vitreal biopsy, or choroidal
sampling. The histology is usually DLBCL. Inasmuch as
PIOL is often a component of PCNSL, the diagnosis should
be made only after MRI and a spinal tap have ruled out
additional sites of CNS involvement. The optimal treatment
approach for PIOL is not well defined. In older series, brain
relapse was almost universal, and some recommended
treating as for PCNSL (22). Recent data suggest that a
substantial number of patients may not experience relapse
Fig. 1. Primary central nervous system lymphoma in a 70-year-old woman: diffuse large B-cell lymphoma. (A) Magnetic
resonance image (MRI) at diagnosis. (B) MRI with complete response after high-dose methotrexatedbased chemotherapy.
(C, D) Whole brain radiation therapy consolidation with 23.4 Gy.
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do, salvage options remain effective when indicated (23,
24). Inasmuch as the globe is not well treated by sys-
temic therapy, radiation may be used as primary therapy;
other options include intraocular methotrexate (25).
Most patients with PIOL present with pathologic or
clinical suspicion of bilateral ocular involvement, and most
treatments have included both eyes, even when pathologic
results have been obtained from only one eye. However,
when there is no suspicion of disease in the contralateral
eye, it is reasonable to treat only the involved eye.Recommendations for planning and treatment follow.
Preplanning studies
 Full ophthalmologic evaluation.
 Brain/orbital MRI and cerebrospinal fluid evaluation.Field
 CTV: the globe of the eye(s), optic nerve (s) to the level
of the chiasm.
Yahalom et al. International Journal of Radiation Oncology  Biology  Physics16 PTV: 5-mm expansion. If both eyes are involved (or there
is suspicion of involvement) an opposed lateral beam
arrangement should include both globes and the optic
nerves to the chiasm. The isocenter should be set at the
posterior border to reduce divergence in case of need for
subsequent WBRT. If only 1 eye is involved, the field is
limited to the involved eye using conformal RT or IMRT
planning.Dose
Dose is 36 Gy.
Dura Mater Lymphoma
Primary dura mater lymphoma is a rare intracranial lym-
phoma that may present with severe neurologic symptoms
and is often suspected to be a meningioma. Lymphoma of
the dura mater is almost always MZL that often remains
localized to dura surfaces, and it is thus potentially curable
with RT alone. Patients are symptomatic and often have
more than 1 lesion (26).Fig. 2. Dura mater lymphoma in a 29-year-old woman with se
treated with 24 Gy whole brain radiation therapy (C) followedRecommendations for planning and treatment follow.
Preplanning studies
Studies include MRI and PET-CT.
Volumes
If more than 1 lesion is present, we recommend treating the
whole brain to 24 Gy and boosting the involved sites with
additional 12 Gy (Fig. 2). A single lesion may be treated
with the presurgical/biopsy MRI volume (GTV) plus mar-
gins constituting the CTV to 30 to 36 Gy.
Dose
Total dose to site: 30 to 36 Gy.
Orbital (Ocular Adnexal) Lymphomas
Most cases of extraocular orbital lymphoma are MZL and
involve the conjunctiva, lacrimal gland, eyelid, or retrobulbarizures and 2 foci of dural marginal zone lymphoma (A, B),
by 12 Gy involved site radiation therapy to lesions (D).
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(synchronous or metachronous) (27, 28). Less common are
FL and DLBCL (28). Careful ophthalmologic assessment
will assist in defining the extent of conjunctival disease
(which is often not fully appreciated on imaging) and in
assessing ocular health before irradiation. CT and MRI of the
orbits, brain, and adjacent sinuses and bony structures are
essential to accurately define the extent of local disease.
Primary RT is considered to be the treatment of choice for
indolent lymphomas (27, 29). Curative RT is appropriate
even for bilateral presentations of indolent lymphoma, which
should be managed as localized disease. RT may also be
used to consolidate systemic therapy for DLBCL.
For retrobulbar, lacrimal gland, and deep conjuctival
lymphomas, the intent is to irradiate the whole orbit; thus,
the CTV is outlined at the orbital bony borders and
expanded to include any areas of definite or suspected bony
or extraorbital extension (rare in MZL) (Fig. 3A, B). Partial
orbital irradiation has been associated with a risk of local
failure (30). Although whole orbit irradiation is generally
recommended, some experts suggest that irradiation of part
of the orbit may be considered in those cases wherein the
resultant morbidity reduction is likely to offset the potential
increase in marginal relapse rate. A technique such as a
superior-inferior wedge pair has the advantage of sparing
the contralateral orbit should metachronous contralateral
disease require RT subsequently (Fig. 3C) (31-33).
For tumors confined to the conjunctiva or eyelid, the irra-
diated volume should include the entire conjunctival reflection
to the fornices, but it need not include the entire orbit. This
situation is usually approached with a direct electron beam
with bolus. In selected cases, a lens shield may be used to
reduce the risk of cataract formation. However, care must be
taken not to shield parts of the conjunctiva because the whole
conjunctival sac is the CTV (Fig. 3).
Immediate toxicity resulting from RT consists of mild to
moderate cutaneous or conjunctival reactions. Long-term
complications are observed in up to 50% of patients. These
complications are relatively minor and include cataract
formation (30%-50%) and mild xerophthalmia (20%-40%).
RT doses above 36 Gy may result in deleterious ophthal-
mologic toxicity such as ischemic retinopathy, optic atro-
phy, corneal ulceration, and neovascular glaucoma,
associated with significant vision loss (33). Smaller daily
fractionations (1.5-1.8 Gy) may be important in reducing
toxicity (33). Although much of the literature describes
doses of 30 to 36 Gy for indolent NHL of the orbit, doses of
24 to 25 Gy provide high rates of local control for MZL and
FL of the orbit, with only modest morbidity (29, 32).
For DLBCL in CR after chemotherapy, the RT dose should
be limited to 30 Gy. In rare circumstances when a radiation
dose higher than 36 Gy is required for patients unfit for
chemotherapy, or with residual disease after chemotherapy,
thewhole orbital dose should be limited to 30 to 36Gy, sparing
the ocular surface and lacrimal glands when possible. Doses
over 36 Gy should be confined to sites of macroscopic disease
using sophisticated planning techniques.Recommendations for planning and treatment follow.
Required preplanning information
 Full ophthalmologic evaluation.
 MRI of orbits and adjacent structures.Volumes: indolent disease
 CTV: for most cases of indolent NHL, the entire bony
orbit including definite or suspected extraorbital exten-
sions. When disease is limited to the conjunctiva, the
CTV includes the entire conjunctival sac and local ex-
tensions to eyelid.
 PTV margin is normally 5 mm.Dose: indolent disease
Dose: 24 to 25 Gy in 1.5- to 2-Gy fractions.
Volumes: DLBCL
 CTV: The entire orbit should be included (Fig. 3). In the
presence of residual disease after chemotherapy, a GTV
should be defined for a boost dose. When DLBCL in-
volves the lacrimal gland alone, the CTV for consolida-
tion RT (after CR to chemotherapy) may be limited to the
lacrimal gland.
 PTV margin is normally 5 mm.Dose: DLBCL
Consolidation after chemotherapy CR: 30 Gy. After partial
response (PR) or relapse, or for use of RT alone, consider
30 to 36 Gy to whole orbit and extensions, shielding
lacrimal gland and avoiding full dose on ocular surface if
appropriate. Residual GTV should be treated to a dose of
40 to 45 Gy depending on the volume and proximity to
critical structures.
Technique
The whole orbit may be treated with 3D conformal RT or
IMRT techniques. The conjunctival sac and lacrimal gland
may be treated with en face electrons. Bolus should be used
in all cases of conjunctival/superficial involvement or defi-
nite or suspected extension. Lens shielding may be used for
disease limited to conjuctiva/eyelid, if appropriate and only
if there is confidence that disease will not be shielded (34).
Lymphomas of the Head and Neck
Planning RT for lymphomas occurring in the head and neck
region requires an understanding of the complex anatomy
of the upper aerodigestive tract and patterns of tumor
spread, high-precision imaging, and meticulous treatment
Fig. 3. Orbital lymphoma in a 58-year-old man with
blurry vision. (A) Magnetic resonance imaging and fluo-
rodeoxyglucose positron emission tomography lead to
diagnosis of marginal zone lymphoma (MZL) with con-
junctiva and choroid involvement. (B) Volumes for in-
tensity modulated radiation therapy: gross tumor volume,
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and long-term toxicity. The pretreatment workup should
include a detailed ENT examination including fiberoptic
examination. In some cases, evaluation with the patient
under general anesthesia with directed biopsies may be
needed to define tumor extent, particularly for low-volume
mucosal/submucosal disease that may be below the reso-
lution of imaging, or when imaging abnormalities are
equivocal. Imaging should include fine-cut CT and PET-CT
in most cases. MRI is useful to evaluate the skull base,
cranial cavity, cranial nerve infiltration, sinuses, and
infratemporal fossa.
Patients generally receive RT to sites of initial definite or
suspected involvement, and prophylactic RT of uninvolved
lymph node regions is not routine. Optimal immobilization
(for example, a 5-point thermoplastic mask) is necessary to
allow tight margins. Treatment techniques used in the
treatment of head and neck cancer (IMRT or 3D conformal
RT) are often appropriate for lymphomas in the same lo-
cations. In the following passage, lymphomas in the
different locations will be described in accordance with the
anatomic sites defined in the TNM classification for solid
tumors arising in the head and neck area.Lymphomas of the Nasal Cavity and Paranasal
Sinuses
Extranodal NK/T-cell lymphomas of the nasal type are
common in certain parts of the world, notably eastern Asia
and South America. This entity has very special clinical
features and is described later in a separate section. In
Western countries, when this location is involved, DLBCL
is the most common histology in these locations, and the
standard treatment is rituximab, cyclophosphamide,
hydroxydaunomycin, oncovin (vincristine), and prednisone
(R-CHOP) with additional therapy for CNS prophylaxis for
some cases, followed by RT (35-38).
Although the principle of ISRT applies to lymphomas in
this anatomic area, the precise delineation of the pre-
chemotherapy tumor extent is often complicated by the
presence of reactive lymphoid tissue and inflammatory
tissue/retained mucus. Minor degrees of tumor involvement
may be below the resolution of PET; conversely, PET scans
may be mildly abnormal in areas of inflammation in the
upper aerodigestive tract. MRI is very useful but may also
fail to distinguish tumor from inflammatory or other benign
changes. Thus, it is often prudent to include the entire
involved structure or cavity.
Similarly, when a neighboring structure is breached (ie a
nasal primary invading adjacent paranasal sinus or orbit),choroidal space, and conjunctiva, red; clinical target vol-
ume, left orbit, yellow; planning target volume, 5 mm, blue.
(C) Alternative approach with conformal superior and
inferior oblique wedges (different orbital MZL case).
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breached structure, depending on confidence regarding
tumor extent and toxicity considerations of enlarging the
fields.
We recommend physical and endoscopic examination,
especially of the upper aerodigestive tract sites to be also
considered in defining the CTV. In some special cases, the
primary lesion cannot be detected by MRI or CT imaging
but can be visible by direct or fiberoptic examination.
Recommendations for planning and treatment follow.
Required preplanning information
PET/CT scans are recommended. For patients with
aggressive lymphomas, prechemotherapy images should be
available, and for lymphomas close to the skull base, MRI
scans are important for detecting possible intracranial
extension.
Volume
 CTV is determined by the prechemotherapy GTV, but
often the entire involved structure is included because of
uncertainty about the exact extent of initial involvement.
Uninvolved sinuses are not included in the CTV, and neck
nodes are treated only if involved.
 PTV margin depends on immobilization, which with
optimal fixation is normally 4 to 5 mm.Dose
Doses are 30 Gy consolidation after CR to chemotherapy,
40 Gy for residual (PR) or uncertain CR. In the rare cases
of indolent lymphomas, the dose is 24 to 30 Gy.
Lymphomas of the Pharynx
Pharyngeal lymphomas often present in Waldeyer’s ring
(WR) (the ring of lymphatic tissue formed by the 2 palatine
tonsils, the nasopharyngeal tonsil, the adenoids in the
posterior wall of the nasopharynx, the lingual tonsil, and
the intervening lymphoid tissue). The most common pre-
sentation is tonsillar DLBCL (39-41). It is usually unilat-
eral and may involve ipsilateral regional lymph nodes
(stage II). The lymphoid tissues of WR have many immune
pathologic characteristics of mucosa-associated lymphoid
tissue (MALT), but interestingly, MALT lymphoma is not
common in WR sites.
The more common aggressive lymphomas are treated
with primary systemic therapy (41-44) followed by ISRT,
with results similar to those in comparably staged nodal
DLBCL (41). For lymphomas close to the skull base,
treatment may include high-dose methotrexate, intrathecal
methotrexate, or both because of the risk of meningeal
involvement. The standard treatment for indolent localized
lymphomas is ISRT alone.The principle of ISRT in the pharynx has been influ-
enced by the Ann Arbor staging system. This system,
originally devised for Hodgkin lymphoma, defined WR as a
single site for staging purposes, which has led many to
consider it as one “involved site” and to treat it often in its
entirety even if only one subsite (eg unilateral tonsil,
nasopharynx) is involved. The ILROG guidelines consider
each of the WR subsites as independent. For DLBCL,
treating the whole WR after chemotherapy is not necessary.
The optimal volume for indolent NHL of WR ring remains
uncertain.
Recommendations for planning and treatment follow.
Required preplanning information
PET/CT scans are recommended. For patients with
aggressive lymphomas, prechemotherapy images should be
available, and for lymphomas close to the skull base, MRI
scans are important for detecting possible intracranial
extension.
Volume
 CTV is determined by the prechemotherapy GTV, but
often the entire involved structure (eg the whole tonsillar
fossa from the level of the soft palate to the level of the
vallecula) is included (Fig. 4) because of uncertainty
about the exact extent of initial involvement. Uninvolved
structures are not included in the CTV, and neck nodes
are treated only if involved.
 PTV margin depends on immobilization; with optimal
fixation it is normally 4 to 5 mm.Dose
Doses are 30 Gy consolidation after CR to chemotherapy;
40 Gy for residual (PR) or uncertain CR. In the rare cases
of indolent lymphomas, the dose is 24 to 30 Gy.
Lymphomas of the Oral Cavity, Larynx, and
Hypopharynx
Involvement with lymphoma is uncommon in these sites. A
range of lymphoma types occurs, including indolent lym-
phomas, mantle cell lymphoma, and DLBCL. Treatment
with RT alone provides excellent local control for indolent
disease, and as in other sites, RT may be given to consol-
idate a chemotherapy response for aggressive NHL.
Defining the GTV may be challenging because of the
limitations of imaging, especially for small mucosal/sub-
mucosal lesions, the difficulties in identifying sharp
boundaries between anatomic subsites, and the small size
of the structures involved. Careful correlation with clinical,
endoscopic, and pathologic findings is essential. Defining
the CTV is also problematic; because of the rarity of
Fig. 4. (A, B) Lymphoma of the tonsil in a 42-year-old man after right tonsillectomy showing diffuse large B-cell lymphoma
of right tonsil alone. (C, D) Received short chemotherapy followed by involved site radiation therapy to tonsil of 30 Gy with
intensity modulated radiation therapy; gross tumor volume, red; clinical target volume, yellow; planning target volume, blue.
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of local microscopic infiltration are lacking.
Rather than site-specific recommendations, it is sug-
gested that definitions of GTV and CTV in these regions
should be generous and reflect the uncertainties listed
earlier.
Recommendations for planning and treatment follow.
Required preplanning information
PET/CT scans are recommended; for patients with
aggressive lymphomas, prechemotherapy images should be
available.
Volume
CTV is determined by the prechemotherapy or prebiopsy
GTV, with margins determined by the quality ofprechemotherapy/surgery information. Often the entire
involved structure (larynx, hypopharynx, or subsite of the
oral cavity) is included because of uncertainty about the
exact extent of initial involvement. Uninvolved structures
are not included in the CTV, and neck nodes are treated
only if involved.
Dose
Doses are 30 Gy consolidation after CR to chemotherapy;
40 Gy for residual (PR) or uncertain CR. For indolent and
mantle cell lymphoma, 24-30 Gy is adequate.
Lymphomas of the Parotid and Other Salivary
Glands
The most common lymphoma type involving the parotid
gland and other salivary glands is MZL (MALT
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with Sjo¨gren syndrome or hepatitis C infection (46). RT is
the treatment of choice for this often localized lymphoma
(47). The rare DBLCL arising in the parotid gland is
usually transformed MZL and is treated with combined
modality therapy.
Recommendations for planning and treatment follow.
RT volume
The CTV is the whole unilateral salivary gland.
Technique
Radiation is 3D conformal RT or IMRT.
Thyroid Lymphoma
The most common lymphomas of the thyroid gland are
DLBCL and MZL. The standard treatment for MZL of the
thyroid is RT alone; DLBCL is treated with R-CHOP fol-
lowed by RT (29, 48-50).
Recommendations for planning and treatment follow.
Field
 The CTV for primary or consolidation RT is the whole
thyroid and should include the prechemotherapy or pre-
resection GTV.
 Planning is with 3D conformal RT or IMRT.
Extranodal NK/T-cell Lymphoma, Nasal Type
Extranodal NK/T-cell lymphoma (NKTCL) nasal type is
relatively common in Asia and South America but is rare
in Western countries (51). It usually involves the nasal
cavity, the paranasal sinuses, or both, but WR may also be
involved. (52). Outside of the upper aerodigestive tract,
the disease presents in advanced stages, with extranodal
dissemination, elevated lactate dehydrogenase levels,
poor performance status, and an unfavorable prognosis
(51, 53).
After the nasal cavity (nasal NKTCL), WR is the second
most common NKTCL site in the upper aerodigestive tract
(52). Compared with nasal NKTCL, WR NKTCL shows a
propensity for nodal involvement, more advanced-stage
disease, more sensitivity to chemotherapy, and a favor-
able prognosis (52).
Recent studies have confirmed that RT is an essential
component of treatment for early-stage NKTCL and be
delivered early in the treatment (54, 55). Optimal out-
comes require doses of 50 Gy for early-stage disease
(56, 57). Local or locoregional control and overall survival
are strongly related (58). The benefit of adding chemo-
therapy to RT for localized disease is unclear. The
apparent benefit of novel chemotherapeutic regimens suchas VIPD (etoposide, ifosfamide, cisplatin, dexametha-
sone) or SMILE (dexamethasone, methotrexate, ifosfa-
mide, L-asparaginase, and etopside) requires further study
(53, 59).
Often NKTCL is locally destructive and may extensively
infiltrate the submucosa beyond macroscopically evident
disease. Hence, the entire involved cavity and adjacent
structures require irradiation.
Recommendations for planning and treatment follow.
Nasal NKTCL
CTV: Limited stage IE (confined to unilateral, anterior or
middle nasal cavity without extension into adjacent or-
gans): CTV covers the bilateral nasal cavity, ipsilateral
maxillary sinus, bilateral anterior ethmoid sinuses, and hard
palate (Fig. 5).
Bilateral nasal cavity involvement: CTV covers the
bilateral nasal cavity, bilateral maxillary sinus, bilateral
anterior ethmoid sinuses, and hard palate.
Nasal tumor located near the posterior nasal aperture
extending into the nasopharynx: CTV should include the
nasopharynx (Fig. 6).
For disease extending into anterior ethmoid sinuses:
CTV should cover the posterior ethmoid sinuses.
For disease extending into adjacent structures (extended
stage I) or with cervical lymph node involvement (stage
IIE): CTV should include involved paranasal organs/tissues
or cervical lymph nodes.
Prophylactic nodal irradiation is not necessary for pa-
tients with nasal NKTCL (60).
Technique: 3D conformal RT or IMRT (58, 61). For pa-
tients with limited stage IE disease, a single anterior port
including the nasal cavity and the ipsilateral maxillary/
ethmoid sinusesmay be used. For patientswith extended stage
IE disease or limited stage IE disease close to the choanae, two
lateral opposing fields and an anteroposterior port may be
used. CTV should encompass the involved paranasal tissues,
nasopharynx, and other adjacent structure or organs.
WR NKTCL
CTV: entire WR, adjacent organs or structures with disease
extension, and cervical lymph nodes (irrespective of gross
involvement of cervical lymph nodes) (Fig. 6) (62, 63).
Inclusion of uninvolved lymph nodes in the CTV is used in
some centers but not in others, where the CTV that some
ILROG experts recommend is confined to the involved site.
When RT is the only treatment, the CTV should include
adjacent structures/tissues as detailed earlier. When effec-
tive chemotherapy (eg SMILE) has preceded RT and has
produced a CR, the CTV should include at least the pre-
chemotherapy GTV with appropriate margins. It should be
emphasized that the experience with the new chemotherapy
regimens and smaller CTV margins in avoiding local
relapse is still limited.
Fig. 5. NK/T cell lymphoma, nasal type. Primary tumor involved the left nasal cavity. Treatment with radiation therapy
alone. Clinical target volume covers the bilateral nasal cavity, left maxillary sinus, and anterior ethmoid sinuses but does not
include the nasopharynx. Dose distribution; (a) transverse, (b) coronal, (c) sagittal planes. d: dose-volume histogram.
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50 Gy with a boost to the residual primary of 5 to 10 Gy. If
RT is given as consolidation after CR to chemotherapy, the
dose is reduced to 45 to 50 Gy.
Breast Lymphoma
DLBCL is the most common breast lymphoma. Indolent
lymphomas such as MZL and FL may also present with
localized breast involvement (64-66). Whole breast irradi-
ation is generally recommended, but some experts consider
partial breast irradiation in cases where the resultant
morbidity reduction is likely to offset the potential increase
in marginal relapse rate.
Recommendations for planning and treatment follow.
Volume
 The CTV for primary or consolidation RT is the whole
breast (Fig. 7). Uninvolved lymph nodes need not be
included.
 Partial breast irradiation is considered by some experts
under special circumstances (as already detailed).Technique
 Breast immobilization with the arm up, or prone tech-
nique for large pendulous breast.
 3D conformal RT using breast tangents or prone
technique.Lymphoma of the Lung
MZL (bronchial associated lymphoid tissue lymphoma
[BALT lymphoma]) may involve any element of the
bronchial tree, often as an isolated lesion (67). The lung
lesion is often fully or partially resected because it is
often treated as a potential lung carcinoma. For incom-
pletely resected or unresectable disease, RT may be
curative. For DLBCL, RT may be used as consolidation
after R-CHOP.
Recommendations for planning and treatment follow.Volumes
 CTV: preintervention (biopsy, resection, or systemic
therapy) GTV that is expanded by clinical judgement to
Fig. 6. NK/T cell lymphoma, nasal type. Primary tumor involved the bilateral nasal cavity extended into the nasopharynx.
Treatmentwith radiation therapy alone. Clinical target volume covers the bilateral nasal cavity, bilateralmaxillary sinuses, anterior
ethmoid sinuses, and nasopharynx. a-c: views of transverse plane; d-e: sagittal plane and lateral field; f: Dose-volume histogram.
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cent microscopic infiltration (Fig. 8).
 ITV: expansion for respiratory motion (use 4D CT if
available, or fluoroscopy).Technique
 Standard body immobilization with the arms up.
 3D conformal or IMRT.
 V20 and pulmonary function status should be taken into
account before the RT plan is selected.
Lymphomas of the Abdomen and Pelvis
Lymphomas may arise in any abdominal or pelvic organ,
the most commonly encountered organs being stomach and
small bowel/mesentery. Several issues are pertinent to the
planning of lymphomas in this region. When irradiating
initially large masses it may be difficult after systemic
chemotherapy to accurately correlate the prechemotherapy
GTV with postchemotherapy residual, particularly because
the organ anatomy may change after a large mass hasresolved. Sometimes a generous CTV volume may be
required to allow for these uncertainties. In addition, many
organs, such as small intestine (Fig. 9), parts of the large
intestine, and to a lesser degree stomach, are partially or
freely mobile within the abdomen. The shape of the
stomach and intestines may also change depending on oral
intake and distension with fluid or gas. Furthermore, most
abdominal and pelvic organs are influenced by movement
during the respiratory cycle. Hence, generating an ITV or
otherwise allowing for motion and variation in organ shape
is vital to ensure adequate coverage of these organs. In this
setting, 4D CT, fluoroscopy, and image guidance can be
useful. Abdominal and pelvic fields are often large, and
several critical organs need to be considered in planning. In
the upper abdomen, complex plans may be required to
minimize kidney, liver, and cardiac irradiation. Gating and
breath holding techniques may allow reduction of exposure
of the cardiac apex and lung base. Split renal function
nuclear scans may allow optimization of planning when a
substantial renal volume cannot be avoided. In the lower
abdomen and pelvis, issues of fertility need to be consid-
ered, along with the impact of larger fields on short-term
and long-term marrow reserve. In some instances,
Fig. 7. Breast lymphoma in a 49-year-old woman, with biopsy of right breast showing diffuse large B-cell lymphoma. (A)
Fluorodeoxyglucose positron emission tomography before chemotherapy). (B) Consolidation involved site radiation therapy
includes the whole right breast to 30 Gy.
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opaque markers may aid in tumor localization.
Gastric Lymphoma
Both MZL (gastric MALT lymphoma [GML]) and DLBCL
occur in the stomach. With the ubiquitous use of EGD,
most gastric lymphomas (GML or DLBCL) are diagnosedFig. 8. Lymphoma of lung in a 62-year-old woman with stage
lymphoid tissue lymphoma) shown on computed tomography (C
(A, B). Plan of involved site radiation therapy for 30 Gy in 15 fra
composed of clinical target volume of 1 cm expanded by 4-dimewhile they are confined to the stomach. Initial therapy of
GML is eradication of Helicobacter pylori, which often
leads to complete regression. When H. pylori is absent or
when GML fails to regress after an appropriate period of
observation, or recurs after eradication of H. pylori, irra-
diation of the stomach is the treatment of choice (6, 68).
Several series have demonstrated an excellent response rate
(95%) of GML with RT to a dose of 30 Gy (often in 1.5 Gy/IAE marginal zone lymphoma of lung (bronchial associated
T) and fluorodeoxyglucose positron emission tomography
ctions (C). Gross tumor volume, red; internal target volume,
nsional CT for respiration; planning target volume (5 mm).
Fig. 9. Mesenteric lymphoma in a 70-year-old man with 3-cm diffuse large B-cell lymphoma. (A, B) Computed tomographic
and fluorodeoxyglucose positron emission tomographic images before chemotherapy. (C) Minor residual after chemotherapy.
Consolidation involved site radiation therapy volumes: gross tumor volume (GTV) and residual GTV, red; clinical target
volume, green; planning target volume, purple.
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good tolerance for treatment and minimal long-term side
effects (29, 69). RT may be used as consolidation treatment
after R-CHOP in DLBCL.
Usually, GML is a multifocal disease, and the entire
stomach should be considered to harbor disease even whenit appears confined to one area. Abnormal or suggestive
perigastric lymph nodes, and rarely portahepatis nodes or
para-aortic nodes. can be encompassed as part of the CTV.
In most cases, the perigastric nodes are simply included in
the RT treatment volume even when they are not patho-
logically confirmed to be involved with lymphoma.
Fig. 9. (Continued).
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detected by 4D CT simulation or by fluoroscopy to
determine the ITV, and an additional margin of approxi-
mately 1 cm is often added to the CTV. The PTV accounts
for setup variation, normally in the range of 1 cm
(Fig. 10A).
Recommendations for planning and treatment follow.
Pretreatment information
 Details of endoscopy findings.
 Endoscopic ultrasonography and directed biopsy in case
of thickened wall/suspected transformation.
 In patients who may receive RT to a large volume of one
kidney, renal scan may provide important information.Simulation
 The stomach volume and position are affected by
ingestion of food or liquids. Patients are always simulated
and treated with an empty stomach after a fast of at least
4 hours or overnight. Patients should be simulated supine with arms up using
customized immobilization device.
 A small volume (<50 mL) of oral contrast medium
should be used in all cases; intravenous contrast me-
dium is recommended if there are suggestive lymph
nodes.
 Images should be acquired before and after oral contrast
medium is given because even small volumes of ingested
contrast medium may lead to stomach dilatation and a
CTV that is not representative of the CTV during
treatment.
 Respiratory motion should be assessed with 4D CT or
fluoroscopy (Fig. 10B).
Volumes
 GTV: Gross disease (if visualized on PET, CT, or both)
and pathologically enlarged lymph nodes.
 CTV: GTV þ stomach volume outlined from gastro-
esophageal junction to beyond the duodenal bulb; the
whole wall is included (perigastric nodes are encom-
passed, if visible).
Fig. 10. (A) Gastric lymphoma in a 65-year-old man with gastric marginal zone lymphoma treated with radiation therapy
alone for 30 Gy. Clinical target volume (CTV), pink; internal target volume after 4-dimensional computed tomography, light
blue; planning target volume, dark blue. (B) Volumes for gastric lymphoma: effect of respiration: CTV at inspiration, yellow;
at expiration, pink.
Volume 92  Number 1  2015 Radiation therapy of extranodal lymphomas 27 ITV is determined by 4D CT or by fluoroscopy to track
variation of stomach position during respiration. An
additional margin of at least 1 to 2 cm is added to the
CTV to accommodate stomach movement.
 PTV is influenced by setup variation; in the abdomen,
1 cm over final ITV is advised.
 Organs at risk volumes for consideration in planning
include kidneys, liver, heart, lungs, bowel, cord.
 Rarely, the duodenum is also involved. In this case,
duodenal volume is included in the CTV.
Technique
Modern RT techniques, including 3D conformal RT and
IMRT, are recommended to reduce radiation of kidneys and
liver and to keep dose as low as reasonably achievable
(Fig. 10) (70).
Duodenal/Small Bowel Lymphoma
Primary duodenal follicular lymphoma is increasingly
recognized and is often detected incidentally during the
endoscopic investigation of abdominal symptoms. It has avery indolent natural history, and many clinicians observe
rather than treat this condition. When RT is considered, a
detailed staging evaluation is mandatory because pill-
camera endoscopy or double balloon/push enteroscopy
detects multifocal disease in many patients. Imaging
including PET may be insensitive to small-volume multi-
focal disease. If disease is localized to the duodenum, RT
can be confined to this organ (71).
Small bowel indolent lymphoma often presents with
pain or obstructive symptoms and is sometimes treated
surgically in the first instance. If disease is confined to
bowel, RT requires whole abdominal irradiation. The use of
whole abdominal irradiation requires due consideration of
possible short-term and long-term toxicity.
Aggressive NHL of the small bowel/mesentery is treated
with chemotherapy, and consolidative RT may be used for
bulky disease. The volume usually reflects the pre-
chemotherapy GTV with appropriate allowance for motion
and uncertainties of location (Fig. 9).Preplanning procedures
 In patients who may receive RT to large volume of 1
kidney or to the whole abdomen, a careful renal
Fig. 10. (Continued).
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titate left versus right kidney function.
Volumes
 CTV: indolent NHL confined to duodenum: the entire
duodenum.
 Aggressive NHL small intestine/mesentery: the volume
should reflect the prechemotherapy GTV with allow-
ance for changes resulting from resolution of the mass.
Structures or organs involved before chemotherapy
should be included when toxicity considerations
permit. Sometimes the postchemotherapy GTV willdetermine the treated volume, or it may define a boost
volumeTechnique
 Simulation: fasting, with oral contrast medium. Organs at
risk should be outlined for treatment planning.
 Indolent NHL of the small bowel or duodenal lymphoma
with involved or uncertain status of small bowel: a
“whole abdominal” technique with low-dose RT may be
used to encompass the entirety of the small intestine and
mesentery.
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Gynecologic Organs
These organs are rarely involved with lymphoma. Most
cases are DLBCL or MZL.
Recommendations for planning and treatment follow.
Simulation
 PET may identify involved sites/nodes.
 Consider whether to simulate and treat with bladder
empty or full.
 Intravenous contrast medium is recommended for simu-
lation if there are involved lymph nodes.Volumes
 CTV: the whole organ should be included in the CTV.
 PTV: the CTV should be expanded to the PTV by 1 cm.
Testicular Lymphoma
The common histology is DLBCL. The primary treatment
is with R-CHOP or more aggressive regimens, and intra-
thecal or intravenous methotrexate is given prophylactically
to address the high risk of CNS relapse. RT is given to the
involved testis (if not resected) and to the remaining testis
and scrotum because of the high risk of relapse in the
contralateral testis (72, 73). RT may be given to involved
abdominopelvic nodes in stage IIE disease.
Recommendations for planning and treatment follow.
Setup
With the patient supine in a frog-leg position, the penis is
lifted and taped to the abdominal wall, and the scrotum is
supported and immobilized with bolus under and around
the scrotum.
Volume
An anterior electron field with energy calculated according
the thickness of the scrotum/testis is set; bolus may be
required.
Dose
Dose to testis: 25 to 30 Gy in 1.5 to 2 Gy per fraction.
Bone Lymphoma
Most patients with bone lymphoma have DLBCL (80% of
cases); other types are relatively rare (74). Approximately
80% of patients present in stage IE; the most common
bones involved are the femurs, pelvic bones, tibia, andfibula; and about 10% of patients have a polyostotic
presentation.
Both MRI and PET/CT are helpful in localizing the
tumor, and PET/CT is particularly useful to evaluate
response to therapy (75).
The standard treatment is with combined modality
therapy with R-CHOP followed by RT (74, 76, 77).
Recommendations for planning and treatment follow.
Volume
 CTV: Prechemotherapy GTV (preferably on MRI) with
margins added to accommodate uncertainties in subclin-
ical tumor extension and quality of imaging and fusion
into simulation CT.
 PTV is between 0.5 and 1 cm depending on site and
immobilization.
Dose
 After chemotherapy, complete regression of PET activity
may not be clear at the time of RT, and dose range is 30 to
40 Gy depending on the certainty that a CR has been
obtained with chemotherapy.
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